FPR1 and Alzheimer disease: In this study, APP/PS1 double-transgenic mice were treated for 20 weeks with the FPR antagonist Boc2, the pro-inflammatory bacterial cell wall component fMLF or the anti-inflammatory FPR agonist Ac2-26 to analyze the effects of an FPR modulation in AD.